Centro de Biotecnología

Abstract

During the past decades the achievements made in treating cancers have significantly improved the survival of patients. However, cancer is still one of the leading causes of mortality. It is suggested that treatment failure is mediated by a subpopulation of tumor cells named cancer stem cells that can survive after treatment and promote cancer relapse. Targeting these cells is important to improve cancer therapy. The aim of our study is to determine the effect of a human ribonuclease variant on breast cancer cells grown in 3D and on cancer stem cells.

Although single targeted anti-cancer drugs are envisaged as safer treatments because they do not affect normal cells, cancer is a very complex disease to be eradicated with a single targeted drug. Alternatively, multi-targeted drugs may be more effective and the tumor cells may be less prone to develop drug resistance although these drugs may be less specific for cancer cells. We have previously developed a new strategy to endow human pancreatic ribonuclease with antitumor action by introducing in its sequence a non-classical nuclear localization signal.

Immune dysfunction in patients with MM affects both the innate and adaptive immune system. Molecules involved in the immune response pathways are essential to determine the ability of cancer cells to escape from the immune system surveillance. However, few data are available concerning the role of immune checkpoint molecules in predicting the myeloma control and immunological scape as mechanism of disease progression. We retrospectively analyzed the clinical impact of the CD200 genotype (rs1131199 and rs2272022) in 291 patients with newly diagnosed MM.

Immune dysfunction in patients with multiple myeloma (MM) affects both the innate and adaptive immune system. Molecules involved in the immune checkpoint pathways are essential to determine the ability of cancer cells to escape from the immune system surveillance. However, few data are available concerning the role of these molecules in predicting the kinetics of progression of MM.

This study aimed to examine the prevalence of comorbidities in patients diagnosed with chronic lymphocytic leukemia (CLL), and to assess its influence on survival and cause-specific mortality at a population-based level. Incident CLL cases diagnosed in the Girona province (Spain) during 2008-2016 were extracted from the Girona Cancer Registry. Rai stage and presence of comorbidities at diagnosis, further categorized using the Charlson comorbidity index (CCI), were obtained from clinical records.

Methods: Data were extracted from the Girona cancer registry. LN incident cases were registered using the ICD-O-3, following the 2008 WHO classification scheme and HAEMACARE grouping. Follow-up was available until the 31/12/2015. Observed and relative survival (RS) were estimated with Kaplan-Meier and Pohar Perme methods, respectively.

We identified 1,102 BTC incident adult cases (>15y), 49.5% females and 50.5% males. Median age at diagnosis was 75y (R25-101). According to histology, 66% of cases were epithelial tumors, 1% neuroendocrine neoplasms, and 2 non-epithelial tumors were detected (1 Lymphoma, 1 sarcoma). The remaining 33% of cases had non-specified histology (“Neoplasm, malignant”). The most frequent subsite was ECC (26.2%), followed by GB (23.2%) and ICC (22.7).

La Amazonia Sur Ecuatoriana, mantiene sus animales bajo sistemas de pastoreo diversos, uno de ellos es el manejo “al sogueo”, conocer información técnica del bovino bajo este sistema es importante. Mediante visita in situ se recopilo información de 80 ganaderías, determinándose un tamaño de las mismas de 11±1.7 Ha, con 9 bovinos (7.2 UBA/predio), predominando los machos (11%); 76.2% de las ganaderías son tipo leche, el 48.7% llevan registros, realizan 2 cambios diarios de pastoreo, la longitud de cuerda es 5.5±0.6 y 3.6±0.7 m (animales grandes y pequeños).

La Brucelosis es una enfermedad infecciosa producida por Brucella mellitensis, siendo la causa más importante de aborto en cabras.